These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34877867)

  • 1. Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer.
    Mei Y; Shi M; Zhu Z; Yuan H; Yan C; Li C; Feng T; Yan M; Zhang J; Zhu Z
    Future Oncol; 2022 Jan; 18(2):139-148. PubMed ID: 34877867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
    Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
    BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective study of adjuvant albumin-bound paclitaxel plus S-1 after D2 gastrectomy versus oxaliplatin plus S-1 in gastric cancer.
    Li N; Wu H; Xu X; Wei Q; Ding Y; Liu S; Wu J; Zheng Y; Xu N; Gao Y; Jiang H
    Sci Rep; 2024 Jul; 14(1):15150. PubMed ID: 38956232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol.
    Cheng X; Wu D; Xu N; Chen L; Yan Z; Chen P; Zhou L; Yu J; Cui J; Li W; Wang C; Feng W; Wei Y; Yu P; Du Y; Ying J; Xu Z; Yang L; Zhang Y
    BMC Cancer; 2021 Jan; 21(1):56. PubMed ID: 33435909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 Study of Combined Chemotherapy of Nab-Paclitaxel, S-1, and Oxaliplatin for Gastric Cancer with Peritoneal Metastasis (NSOX Study).
    Nakamura M; Ojima T; Katsuda M; Hayata K; Kitadani J; Nakamori M; Yamaue H
    Oncology; 2021; 99(1):57-61. PubMed ID: 32877909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II clinical trial of S-1 plus nanoparticle albumin-bound paclitaxel in untreated patients with metastatic gastric cancer.
    He MM; Wang F; Jin Y; Yuan SQ; Ren C; Luo HY; Wang ZQ; Qiu MZ; Wang ZX; Zeng ZL; Li YH; Wang FH; Zhang DS; Xu RH
    Cancer Sci; 2018 Nov; 109(11):3575-3582. PubMed ID: 30281875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases.
    Shi M; Yang Z; Lu S; Liu W; Ni Z; Yao X; Hua Z; Feng R; Zheng Y; Wang Z; Sah BK; Chen M; Zhu Z; He C; Li C; Zhang J; Yan C; Yan M; Zhu Z
    BMC Cancer; 2021 Dec; 21(1):1344. PubMed ID: 34922478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer.
    Kawamoto Y; Komatsu Y; Yuki S; Sawada K; Muranaka T; Harada K; Nakatsumi H; Fukushima H; Ishiguro A; Dazai M; Hatanaka K; Nakamura M; Iwanaga I; Uebayashi M; Sogabe S; Kobayashi Y; Miyagishima T; Ono K; Sakamoto N; Sakata Y
    BMC Cancer; 2017 Dec; 17(1):837. PubMed ID: 29221445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
    Ishikawa M; Iwasa S; Nagashima K; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Saruta M; Boku N
    Invest New Drugs; 2020 Apr; 38(2):533-540. PubMed ID: 31264067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of chemotherapy for patients with gastric cancer with early recurrence during or after adjuvant chemotherapy with S-1 alone: a multicenter retrospective study.
    Yamaguchi T; Kumagai K; Yagi S; Nomura T; Nagashima K; Watanabe M; Makuuchi R; Kawakami K; Matsushima T; Kadowaki S; Haruta S; Cho H; Kakihara N; Otsuka S; Yamada T; Imai Y; Boku N
    Sci Rep; 2024 Sep; 14(1):21854. PubMed ID: 39300169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 Dose-Escalation Study of Triweekly Nab-Paclitaxel Combined With S-1 for HER2-Negative Metastatic Breast Cancer.
    Morimoto M; Toba H; Aoyama M; Nakagawa M; Takechi H; Yoshida T; Tangoku A
    Clin Breast Cancer; 2020 Dec; 20(6):448-453. PubMed ID: 32800494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial).
    Zhou N; Li X; Yang Y; Tan S; Zhang S; Huang Q; Gou H
    BMC Cancer; 2023 Aug; 23(1):729. PubMed ID: 37550655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer.
    Nakayama N; Ishido K; Chin K; Nishimura K; Azuma M; Matsusaka S; Inokuchi Y; Tanabe S; Kumekawa Y; Koizumi W
    Gastric Cancer; 2017 Mar; 20(2):350-357. PubMed ID: 27189323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial.
    Ishigami H; Fujiwara Y; Fukushima R; Nashimoto A; Yabusaki H; Imano M; Imamoto H; Kodera Y; Uenosono Y; Amagai K; Kadowaki S; Miwa H; Yamaguchi H; Yamaguchi T; Miyaji T; Kitayama J
    J Clin Oncol; 2018 Jul; 36(19):1922-1929. PubMed ID: 29746229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
    Jiang H; Qian J; Zhao P; Zhang X; Zheng Y; Mao C; Zheng Y; Chen L; Wang Y; Mou H; Fang W; Teng L; Xu N
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):197-203. PubMed ID: 26013324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings.
    Ishigami H; Yamaguchi H; Yamashita H; Asakage M; Kitayama J
    Gastric Cancer; 2017 Mar; 20(Suppl 1):128-134. PubMed ID: 28028665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Camrelizumab in Combination With Nab-Paclitaxel Plus S-1 for the Treatment of Gastric Cancer With Serosal Invasion.
    Lin JL; Lin JX; Lin JP; Zheng CH; Li P; Xie JW; Wang JB; Lu J; Chen QY; Huang CM
    Front Immunol; 2021; 12():783243. PubMed ID: 35116023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.
    Kitayama J; Ishigami H; Yamaguchi H; Yamashita H; Emoto S; Kaisaki S; Watanabe T
    Ann Surg Oncol; 2014 Feb; 21(2):539-46. PubMed ID: 23975319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized phase II study of S-1 monotherapy versus cisplatin with vinorelbine for completely resected stage II/IIIA non-small cell lung cancer: rationale and study protocol design for the LOGIK1702 study.
    Tsuchiya T; Matsumoto K; Miyazaki T; Doi R; Tokunaga S; Yamaguchi H; Tomoshige K; Watanabe H; Nagayasu T; Sugio K
    BMC Cancer; 2021 Mar; 21(1):249. PubMed ID: 33685421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the INPACT study, a randomized controlled trial.
    Kodera Y; Takahashi N; Yoshikawa T; Takiguchi N; Fujitani K; Ito Y; Miyamoto K; Takayama O; Imano M; Kobayashi D; Miyashita Y; Morita S; Sakamoto J
    Gastric Cancer; 2017 Jan; 20(1):190-199. PubMed ID: 26879545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.